Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · October 11, 2023

hs-cTnI–Guided Combination Therapy With Carvedilol and Candesartan to Prevent Anthracycline Cardiotoxicity Among Patients With Breast Cancer or Non-Hodgkin Lymphoma



Additional Info

Disclosure statements are available on the authors' profiles:

Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial
Circulation 2023 Sep 25;[EPub Ahead of Print], PA Henriksen, P Hall, IR MacPherson, SS Joshi, T Singh, M Maclean, S Lewis, A Rodriguez, A Fletcher, RJ Everett, H Stavert, A Broom, L Eddie, L Primrose, H McVicars, P McKay, A Borley, C Rowntree, S Lord, G Collins, J Radford, A Guppy, MC Williams, A Japp, JR Payne, DE Newby, NL Mills, O Oikonomidou, NN Lang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading